PAPER Pedrero-Chamizo R, Zhuang K, Juarez A, Janabi M, Jagust WJ, Landau SM

Alzheimer's disease prevention: Apolipoprotein e4 moderates the effect of physical activity on brain beta-amyloid deposition in healthy older adults.

J Sci Med Sport. 2024 Apr 3; PubMed: 38664148

PAPER Rotstein A

Adult-Onset Attention-Deficit/Hyperactivity Disorder and the Risk of Lewy Body Dementia: An Invited Commentary.

Am J Geriatr Psychiatry. 2024 Apr 10; PubMed: 38664081

PAPER Korologou-Linden R, Xu B, Coulthard E, Walton E, Wearn A, Hemani G, White T, Cecil C, Sharp T, Tiemeier H, Banaschewski T, Bokde A, Desrivières S, Flor H, Grigis A, Garavan H, Gowland P, Heinz A, Brühl R, Martinot JL, Paillère Martinot ML, Artiges E, Nees F, Orfanos DP, Paus T, Poustka L, Millenet S, Fröhner JH, Smolka M, Walter H, Winterer J, Whelan R, Schumann G, Howe LD, Ben-Shlomo Y, Davies NM, Anderson EL

Genetics impact risk of Alzheimer's disease through mechanisms modulating structural brain morphology in late life.

J Neurol Neurosurg Psychiatry. 2024 Apr 25; PubMed: 38663994

PAPER Carr LM, Mustafa S, Care A, Collins-Praino LE

More than a number: Incorporating the aged phenotype to improve in vitro and in vivo modeling of neurodegenerative disease.

Brain Behav Immun. 2024 Apr 23; PubMed: 38663775

PAPER Nozal V, Fernández-Gómez P, García-Rubia A, Martínez-González L, Cuevas EP, Carro E, Palomo V, Martínez A

Designing multitarget ligands for neurodegenerative diseases with improved permeability trough PLGA nanoencapsulation.

Biomed Pharmacother. 2024 Apr 24;175:116626. PubMed: 38663103

PAPER Orlandi F, Carlos AF, Ali F, Clark HM, Duffy JR, Utianski RL, Botha H, Machulda MM, Stephens YC, Schwarz CG, Senjem ML, Jack CR, Agosta F, Filippi M, Dickson DW, Josephs KA, Whitwell JL

Histologic tau lesions and magnetic resonance imaging biomarkers differ across two progressive supranuclear palsy variants.

Brain Commun. 2024;6(2):fcae113. Epub 2024 Apr 5 PubMed: 38660629

PAPER Fu Y, Wang Y, Ren H, Guo X, Han L

Branched-chain amino acids and the risks of dementia, Alzheimer's disease, and Parkinson's disease.

Front Aging Neurosci. 2024;16:1369493. Epub 2024 Apr 10 PubMed: 38659706

PAPER Wang S, Xie S, Zheng Q, Zhang Z, Wang T, Zhang G

Biofluid biomarkers for Alzheimer's disease.

Front Aging Neurosci. 2024;16:1380237. Epub 2024 Apr 10 PubMed: 38659704

PAPER Mollah SA, Nayak A, Barhai S, Maity U

A comprehensive review on frontotemporal dementia: its impact on language, speech and behavior.

Dement Neuropsychol. 2024;18:e20230072. Epub 2024 Apr 22 PubMed: 38659629

PAPER Yang LX, Luo M, Li SY

Tanshinone IIA improves Alzheimer's disease via RNA nuclear-enriched abundant transcript 1/microRNA-291a-3p/member RAS oncogene family Rab22a axis.

World J Psychiatry. 2024 Apr 19;14(4):563-581. PubMed: 38659601

Robert Sobolewski

Massachusetts General Hospital
Charlestown, United States

Thomas Foltynie on Diabetes Drug Shows Promise for Parkinson’s Disease

COMMENT This is an important publication, given it essentially replicates the findings of Athauda et al., who reported positive Phase 2 data of a very similar GLP-1 receptor agonist drug, exenatide, when given to patients with Parkinson’s disease (Athauda et al.,

Oscar Mailman

Pittsburgh, United States

Nazaret Gamez

Houston Methodist Research Institute
Houston, United States

Sandrine Legg

Alchemab Therapeutics